MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression

Table 1 Expression of MALAT1 in patients with multiple myeloma and healthy individuals

Population	No.	Expression of MALAT1 (Mean ΔC_T)
Newly diagnosed	45	-5.54 ± 0.16
Post-treatment	61	-3.84 ± 0.09
Relapse or progression	18	-4.92 ± 0.23
Healthy individuals	20	-3.95 ± 0.21
	ΔΔC_T	Fold change	P value
Newly diagnosed vs. Post-treatment	-1.70	3.25	<0.001
Newly diagnosed vs. Healthy individuals	-1.59	3.01	<0.001
Relapse or progression vs. Post-treatment	-0.92	1.89	<0.001
Post-treatment vs. Healthy individuals	0.11	1.08	0.614

The 61 post-treatment samples were composed of 58 samples collected in disease status of VGPR or CR from 42 patients. The percentages of plasma cells were all less than 5%.
The 3 samples collected at a disease status of partial response came from 3 patients.
Note:
ΔC_T = C_T (MALAT1 - GAPDH).
Increased expression (fold change) was calculated as 2^-ΔΔCT.

ISSN: 1471-2407